Pfizer's Long March Through China's Courts
Pfizer (PFE) executives had reason to be in a celebratory mood in early June. The pharmaceutical giant won an appeal in Beijing on June 2 that overturned a 2004 decision to invalidate the patent Pfizer obtained five years ago to produce the anti-impotency drug Viagra in China. The decision was hailed as a landmark victory for intellectual property rights in the Middle Kingdom, where all too often the odds are stacked against foreign companies.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.